08:00 , Nov 7, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Fibrillin 1 (Fbn1)-mutant mouse models of systemic scleroderma Mice harboring mutations in the integrin-binding...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

arGentis, University of Tennessee deal

arGentis received exclusive, worldwide rights to the university's ARG301 to treat rheumatoid arthritis. The oral synthetic peptide targeting Type II collagen is in preclinical development. Financial terms were not disclosed. arGentis' ARG201 type...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

ARG201 regulatory update

EMEA granted Orphan Drug designation for arGentis' ARG201 to treat diffuse systemic sclerosis. The type I native bovine collagen, which also has Orphan designation in the U.S., has completed a Phase II trial for...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

ARG201 regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for ARG201 to treat systemic sclerosis. arGentis has completed a Phase II trial of the type I native bovine...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Clinical News

ARG201: Phase II data

In a double-blind, U.S. Phase II trial in 168 patients, oral ARG201 missed the primary endpoint of a significant improvement in MRSS vs. placebo. In a prospectively defined subgroup of late phase patients (diagnosed from...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Clinical News

ARG201: Phase III start

In 1H09, arGentis will begin 2 identical, double-blind, international Phase III trials of oral ARG201. Each trial will enroll about 125 late phase patients. ARG201 has Orphan Drug designation in the U.S. arGentis Pharmaceuticals LLC,...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Clinical News

ARG201 regulatory update

FDA granted Orphan Drug designation for ARG201 to treat diffuse systemic sclerosis. arGentis has completed a Phase II trial of the solubilized type I native bovine collagen for the indication. arGentis Pharmaceuticals LLC, Memphis,...
07:00 , Aug 20, 2007 |  BC Week In Review  |  Company News

arGentis, University of Tennessee deal

arGentis received an exclusive, worldwide license to the university's ARG201, a solubilized type I native bovine collagen, to treat systemic sclerosis and other fibrosing diseases. Last year, ARG201 completed a Phase II trial to...